# A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07076095/  
OnCo record `nct07076095` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in lung cancer, run by SUNHO（China）BioPharmaceutical CO., Ltd., not yet recruiting.

## Summary

A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer is a phase 2, interventional study registered as NCT07076095 by SUNHO（China）BioPharmaceutical CO., Ltd., with a registry enrolment figure of 200 participants, started 2025-08-01 and due to reach its primary completion in 2028-08-01. Interventions recorded: IBB0979; topotecan hydrochloride for injection. Conditions listed: Small Cell Lung Cancer. Primary outcome: Frequency of adverse events (AEs) and SAEs (Phase II). Lung eligibility wording from the registry: "Histologically confirmed SCLC". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07076095
- Phase: 2
- Setting: A Phase II/III Study to Compare IBB0979 in Combination With Topotecan Versus Topotecan in Subjects With Relapsed Small Cell Lung Cancer
- Sponsor: SUNHO（China）BioPharmaceutical CO., Ltd.
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT07076095: https://clinicaltrials.gov/study/NCT07076095

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/)
- companies: [SunHo Biopharmaceutical](https://onco.cc/companies/sunho-biopharmaceutical/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07076095.json